

## Oncologist-approved cancer information from the American Society of Clinical Oncology

Home > About Us > Cancer.Net Editorial Board > Associate Editors

Printed July 25, 2014 from http://www.cancer.net/about-us/cancernet-editorial-board/associate-editors/anas-younes-md

## Anas Younes, MD



## Cancer.Net Associate Editor, Social Media

Memorial Sloan Kettering Cancer Center

Dr. Anas Younes is a board-certified medical oncologist and is currently Chief of Memorial Sloan Kettering's Lymphoma Service in the Division of Hematologic Oncology, Department of Medicine.

Before joining Memorial Sloan Kettering in 2013, Dr. Younes served as Director of Clinical Investigation and Translational Research in the Department of Lymphoma/Melanoma at the University of Texas M. D. Anderson Cancer Center, in Houston. He received his medical degree from the University of Damascus School of Medicine, in Syria in 1983. After completing residencies in internal medicine and pathology at the State University of New York Downstate Medical Center, in Brooklyn, and the Medical College of Ohio, in Toledo, Dr. Younes completed a hematology/oncology fellowship at Memorial Sloan Kettering in 1992.

As Chief of Memorial Sloan Kettering's Lymphoma Service, Dr. Younes is responsible for continuing to accelerate the translation of scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin and non-Hodgkin lymphoma.

Dr. Younes has served as the principal investigator of more than 60 clinical trials, and led the National Cancer Institute?funded SPORE (Specialized Programs of Research Excellence) in lymphoma. He serves on the Scientific Advisory Board of the Lymphoma Research Foundation, and is a member of the National Cancer Institute Lymphoma Steering Committee.

Disclosure: In the past two years, Dr. Younes has served as a consultant/advisor for Gilead Sciences, Incyte, Seattle Genetics, Novartis, Celgene, Millennium, and Sanofi, received honoraria from Gilead Sciences, Incyte, Seattle Genetics, Novartis, Celgene, Novartis, Millennium, and Sanofi, and received research funding from Gilead Sciences, Curis, Janssen, and Novartis.